Filella X, Blade J, Guillermo A L, Molina R, Rozman C, Ballesta A M
Department of Clinical Biochemistry (Unit Cancer Research), Barcelona, Spain.
Cancer Detect Prev. 1996;20(1):52-6.
The serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), soluble interleukin-2 receptor (sIL-2r), and interleukin-1alpha (IL-1alpha) were measured in 30 healthy subjects, 22 patients with monoclonal gammopathy of undetermined significance (MGUS), five patients with smoldering multiple myeloma (SMM), and 46 with multiple myeloma (MM). Serum levels of IL-6, TNF-alpha, and sIL-2r were significantly increased in patients with active MM when compared with normal controls. Furthermore, MM patients with advanced aggressive disease had significantly higher levels of IL-6, TNF-alpha, and sIL-2r than those with MM in plateau phase. In conclusion, our data support the involvement of IL-6, TNF-alpha, and sIL-2r in MM. This confirms recent in vitro studies suggesting that these cytokines may play a central role in the pathogenesis of MM. Our data also show that serum levels of TNF-alpha, sIL-2r, and, particularly, IL-6 could be useful in the clinical management of patients with MM.
在30名健康受试者、22名意义未明的单克隆丙种球蛋白病（MGUS）患者、5名冒烟型多发性骨髓瘤（SMM）患者和46名多发性骨髓瘤（MM）患者中检测了白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、可溶性白细胞介素-2受体（sIL-2r）和白细胞介素-1α（IL-1α）的血清水平。与正常对照组相比，活动性MM患者的IL-6、TNF-α和sIL-2r血清水平显著升高。此外，晚期侵袭性疾病的MM患者的IL-6、TNF-α和sIL-2r水平显著高于平台期MM患者。总之，我们的数据支持IL-6、TNF-α和sIL-2r参与MM。这证实了最近的体外研究，表明这些细胞因子可能在MM的发病机制中起核心作用。我们的数据还表明，TNF-α、sIL-2r，特别是IL-6的血清水平可能对MM患者的临床管理有用。
